Long-Term Weight Loss with GLP-1 Agonists: What to Expect

GLP-1 agonists are medications that help with weight loss and improve metabolic health, especially for women with PCOS. They work by controlling appetite, slowing digestion, and improving insulin sensitivity. Here’s what you need to know:

• Short-Term Results (3–6 months): Most people lose 5–10% of their body weight. For example, a 2025 study showed an average loss of 7.9 to 12 lbs in PCOS patients.
• Long-Term Results (1–3 years): Sustained weight loss of 10–15% is typical, with results peaking around 12–18 months. Weight plateaus are common after 1–1.5 years.
• Stopping Treatment: Weight regain often occurs after discontinuation, typically two-thirds of lost weight within a year. Combining GLP-1 agonists with metformin or exercise helps reduce regain.
• Other Benefits: Lower testosterone levels, improved menstrual cycles, better blood sugar control, and reduced cardiovascular risks.

While side effects like nausea are common, they’re usually mild and temporary. Regular medical check-ins ensure safe and effective use. If managing PCOS, pairing GLP-1 treatments with lifestyle changes and ongoing support can lead to better outcomes.

Weight Loss Results in the First 3-6 Months

How Much Weight to Expect Early On

In the first 3–6 months, many individuals with PCOS see noticeable weight loss. A 2025 meta-analysis involving 397 women with PCOS revealed that those using GLP-1 agonists for at least 12 weeks lost an average of 7.9 lbs (3.57 kg). When compared to a placebo, the average weight loss increased to 12 lbs (5.44 kg).

One study found that 77% of PCOS patients lost more than 5% of their total body weight, and 55% achieved weight loss exceeding 10%. Another study focusing on liraglutide users reported that 85.6% of participants lost more than 4.4 lbs (2 kg) within 50 days, with an average loss of 10.8 lbs (4.9 kg).

In April 2024, researchers at the University Medical Centre Ljubljana in Slovenia conducted a study involving 25 women with PCOS and obesity. Participants received semaglutide (1.0 mg weekly) alongside metformin and made lifestyle changes. Over 16 weeks, the median body weight dropped from 223 lbs (101 kg) to 203 lbs (92 kg). By the end of the study, all participants had achieved normal glucose tolerance.

Now, let’s explore the factors that can influence these early outcomes.

What Affects Your Initial Results

Several elements can impact how much weight you lose during the first few months. The type and dosage of medication play a major role. For instance, dual-receptor agents like tirzepatide, as well as higher doses, are linked to greater weight loss. Additionally, women without type 2 diabetes tend to experience more pronounced weight loss compared to those managing both PCOS and diabetes.

Lifestyle changes are just as important. According to Patrick Welch, PharmD, BCACP, incorporating lifestyle adjustments significantly improves results. Pairing medication with at least 150 minutes of physical activity per week and following a low-glycemic or reduced-carbohydrate diet can enhance weight loss even further. Interestingly, experiencing nausea - though unpleasant - has been associated with better weight loss outcomes. Lastly, sticking closely to the prescribed treatment schedule is crucial for maximizing effectiveness.

Weight Loss After 1-3 Years of Treatment

Long-Term Weight Loss Data

Using GLP-1 agonists over the long term helps sustain weight loss for several years. For example, the SELECT trial revealed that patients on semaglutide maintained an average weight loss of -10.2% over four years (208 weeks), while the placebo group only saw a modest -1.5% reduction. Similarly, the STEP 5 trial demonstrated even greater results, with participants achieving a mean weight loss of -15.2% after two years (104 weeks).

Most individuals experience a weight loss plateau between weeks 60 and 65 of treatment. At this stage, weight tends to stabilize rather than continue dropping. This plateau indicates that the body has reached a new balance, not that the medication has stopped working. In the two-year STEP 5 study, 77.1% of participants lost at least 5% of their body weight, and 36.1% achieved a reduction of 20% or more. These findings provide valuable insights into what happens when treatment ends and weight regain dynamics come into play.

For patients with PCOS, long-term treatment offers additional benefits. Even after stopping semaglutide, improvements in hormonal profiles - such as lower free testosterone levels - are maintained when metformin is continued. This is crucial because elevated testosterone levels contribute to common PCOS symptoms like irregular periods and excess facial hair.

Weight Regain After Stopping Treatment

While GLP-1 treatments deliver sustained benefits during use, discontinuing them often leads to weight regain. Stopping GLP-1 medications typically results in a significant return of lost weight. For instance, the STEP 1 extension study found that participants regained about two-thirds of their lost weight within a year of stopping semaglutide. Similarly, in the SURMOUNT-4 trial, patients who transitioned from tirzepatide to a placebo experienced a 14% weight regain by week 88.

This weight regain occurs because the medication’s appetite-suppressing effects and reduction in "food noise" diminish within five to seven weeks after the last dose. Additionally, the body’s metabolic rate tends to decrease following weight loss, triggering processes that promote weight regain.

However, PCOS patients may have a unique advantage. Research suggests that continued metformin use and structured exercise programs can help reduce weight regain. A study conducted at the University Medical Centre Ljubljana in Slovenia followed 25 women with PCOS who were treated with semaglutide (1.0 mg weekly) and metformin for 16 weeks. After discontinuing semaglutide but continuing metformin for two years, they regained only one-third of their lost weight, with 21 out of 25 women maintaining a lower weight than their starting baseline. Similarly, the S-LiTE trial in Copenhagen (2018–2020) tracked 109 adults with obesity. Participants who combined liraglutide (3.0 mg) with supervised exercise maintained at least 10% weight loss one year after stopping all treatments. By contrast, those who relied on liraglutide alone regained an average of 21.2 lbs (9.6 kg) during the same period.

"If you have struggled with your weight and been unable to keep off the weight you have lost in the past... please consider staying on them for a long time. Stop the struggle." - Craig Primack, MD, Obesity Medicine Physician, Hims & Hers

To reduce the likelihood of weight regain when discontinuing treatment, experts recommend tapering the dose under medical supervision, consuming around 100 grams of protein daily, and incorporating bi-weekly strength training to preserve muscle mass and maintain a higher metabolic rate.

Health Benefits Beyond Weight Loss

Improvements in Blood Sugar and Heart Health

GLP-1 agonists are not just about weight management - they also play a crucial role in improving metabolic health. These medications work by stimulating insulin release only when necessary and suppressing glucagon, which helps prevent blood sugar swings and episodes of hypoglycemia. They also slow down how quickly the stomach empties, reducing the likelihood of sudden blood sugar spikes after meals.

For women with PCOS, this is particularly impactful, as insulin resistance affects 50% to 90% of them. A 2024 meta-analysis focusing on PCOS patients revealed that GLP-1 receptor agonists significantly lowered fasting insulin levels, improved results on the 2-hour post–oral glucose tolerance test, and reduced HOMA-IR, a key marker of insulin resistance. Additionally, these medications helped lower hemoglobin A1c by about 1% compared to control groups. These metabolic improvements set the stage for better hormonal balance and more regular menstrual cycles.

The cardiovascular advantages of GLP-1 receptor agonists go beyond blood sugar management. Long-term use has been shown to reduce the risk of major cardiovascular events by 14%, all-cause mortality by 12%, and hospitalizations for heart failure by 11%. In the STEP 1 trial, participants taking semaglutide saw a reduction in systolic blood pressure by 6.16 mm Hg, compared to just 1.06 mm Hg in the placebo group. Women with PCOS also experienced reductions in waist circumference (an average decrease of 5.16 cm, or about 2 inches) and triglyceride levels (lowered by 0.20 mmol/L, or roughly 18 mg/dL). Moreover, hypertension resolution was achieved in 23% of those treated with GLP-1 agonists, compared to 11% in the placebo group.

"GLP-1 receptor agonists do more than regulate blood sugar - they also protect the heart. Clinical trials have shown that these medications reduce the risk of major cardiovascular events, including heart attack and stroke." - UC Davis Health

Better Menstrual Cycles and Hormone Levels

The benefits of improved insulin sensitivity extend beyond blood sugar control, particularly for women with PCOS. By addressing insulin resistance both throughout the body and within the ovaries, GLP-1 agonists help restore hormonal balance. High insulin levels can trigger the ovaries to produce too many androgens, which disrupt normal follicle development and ovulation. By improving insulin sensitivity, these medications help regulate the hormonal environment needed for consistent menstrual cycles.

Long-term studies consistently report sustained hormonal improvements in women with PCOS. Free testosterone levels drop significantly during treatment, and these benefits often remain stable even after stopping GLP-1 therapy, provided metformin is continued.

These hormonal changes lead to better menstrual regularity and fertility outcomes. By reducing androgens and improving insulin resistance, GLP-1 agonists support regular ovulation, making them a promising option for addressing PCOS-related infertility. Furthermore, long-term use of these medications has been shown to reduce the risk of developing type 2 diabetes by sevenfold compared to placebo.

Side Effects and Medical Monitoring

Common Side Effects to Expect

When starting GLP-1 agonists, gastrointestinal issues are the most frequent side effects, especially in the early weeks or when increasing the dosage. In a two-year clinical trial, 82.2% of participants taking semaglutide reported gastrointestinal symptoms, compared to 53.9% in the placebo group. Similarly, a study on women with PCOS found that about 44% experienced mild gastrointestinal effects when semaglutide was combined with metformin.

These side effects are usually mild and temporary. Nausea, for instance, affects roughly 40.2% to 44.2% of patients but tends to subside as the body adjusts to the medication. To ease nausea, try eating smaller, bland meals like crackers or bananas, stay hydrated, and avoid greasy or spicy foods. Sitting upright for at least 30 minutes after eating can also help reduce heartburn and bloating.

Although rare, serious side effects demand immediate medical attention. Severe abdominal pain could indicate conditions like acute pancreatitis, gallbladder issues, or bowel obstruction. Injection site reactions, such as redness or swelling, can often be managed by rotating the injection site between the abdomen, thigh, or upper arm.

"Most side effects of GLP-1 and GLP-1/GIP RAs involve gastrointestinal symptoms, are mild-to-moderate, and improve with time." - Maria D. Hurtado, MD, Mayo Clinic

While side effects are a common part of treatment, regular monitoring ensures the therapy remains safe and effective.

Regular Check-Ups and Lab Tests

To manage GLP-1 therapies effectively, it's essential to work with a healthcare provider experienced in these treatments. Your doctor will monitor key health metrics like weight, blood pressure, and resting heart rate, as GLP-1 medications may increase your heart rate by 2.5 to 3.5 beats per minute. Routine lab tests often include HbA1c, fasting glucose, insulin levels (HOMA-IR), lipid panels, and kidney function tests.

For women with PCOS, additional monitoring might involve tracking menstrual cycle patterns and hirsutism scores to evaluate hormonal changes. Providers typically adjust the dosage every four weeks to strike the right balance between effectiveness and minimizing side effects, tailoring the treatment to your needs.

"It is of utmost importance that these medications are taken under the supervision of a health care professional trained and knowledgeable on the use of these medications." - Maria D. Hurtado, MD, Mayo Clinic

If you’re planning surgery, let your anesthesiologist know about your GLP-1 use. These medications slow stomach emptying, which can increase the risk of aspiration during anesthesia.

sbb-itb-6dba428

Can GLP-1 help with PCOS symptoms? What the weight-loss drugs may mean for women's treatment.

How Oana Health Supports PCOS Weight Management

Oana Health provides telehealth solutions specifically designed to support women in managing PCOS-related weight challenges over the long term.

GLP-1 Treatment Options at Oana Health

Oana Health offers convenient, injection-free treatments tailored for women with PCOS. Their Oral Semaglutide GLP-1 treatment and the Oral GLP-1 & Metformin combination are both available for $199 per month, with free shipping included. The combination therapy addresses weight management while also targeting metabolic health concerns.

The oral format makes these treatments more accessible for those who prefer to avoid injections. Licensed healthcare professionals develop personalized care plans that take into account PCOS-specific issues such as hormonal imbalances, irregular menstrual cycles, and insulin resistance. This targeted medication approach ensures that each patient receives care tailored to their unique needs, creating a foundation for consistent and effective management.

Why Choose Oana Health

Oana Health goes beyond medication by providing ongoing, personalized support. Through regular check-ins and continuous monitoring, licensed professionals track your progress and adjust your treatment plan as needed. This ensures that your therapy evolves alongside your body's response, offering a dynamic approach to managing PCOS.

The combination therapy option is particularly effective for long-term weight maintenance. Research highlights the benefits of combining Metformin with GLP-1 treatments. For instance, studies show that PCOS patients who continued using Metformin after stopping semaglutide regained only one-third of their weight loss over two years, compared to two-thirds in patients who did not use Metformin. By offering this combination at an accessible price, Oana Health prioritizes sustainable results rather than focusing solely on short-term weight loss.

With Oana Health's telehealth model, you can access specialized PCOS care from the comfort of your home, eliminating the need for in-person visits. Their approach emphasizes overall health improvements, monitoring not just weight but also hormonal balance, menstrual cycle regularity, and metabolic health markers. This comprehensive care ensures that your treatment addresses the full spectrum of PCOS-related concerns.

What to Expect with GLP-1 Agonists

GLP-1 agonists have shown impressive results for weight loss in patients with PCOS, with benefits that continue to improve over time. Within just 3 to 6 months, nearly 80% of obese PCOS patients lose at least 5% of their body weight - often around 25 pounds. Weight loss typically reaches its peak between 12 and 18 months. Research indicates that patients undergoing GLP-1 therapy lose an average of 10.6% of their total body weight, compared to just 3.9% for those on a placebo.

But the benefits don’t stop at weight loss. GLP-1 agonists also reduce fasting insulin levels, improve glucose tolerance, and lower total testosterone by about 33%. For many, this leads to normalized menstrual cycles in 80% of patients. Additionally, these therapies can cut cardiovascular risk by 20%, offering metabolic advantages that go hand-in-hand with the weight loss outcomes.

"Treatment with semaglutide, at low doses, significantly reduces body weight in almost 80% of obese PCOS patients who were unresponsive to a previous lifestyle plan." - Enrico Carmina, MD

This highlights how critical it is to stay consistent with treatment to achieve and maintain these results. Discontinuing GLP-1 therapy often leads to weight regain, which is why Oana Health focuses on promoting sustainable, long-term approaches for its patients.

Side effects? They’re typically mild and temporary, often resolving as doses are gradually increased. Regular telehealth check-ins are part of the process, allowing your treatment to adapt to your body’s needs. These check-ins monitor not only weight but also hormonal health, menstrual regularity, and overall metabolic well-being.

FAQs

What benefits do GLP-1 agonists offer for women with PCOS?

GLP-1 receptor agonists bring several benefits to women managing PCOS, especially when it comes to weight control and metabolic health. These medications are known to help with significant weight loss by curbing appetite and promoting better hormonal regulation. This can be particularly helpful in addressing PCOS-related challenges such as irregular menstrual cycles and hormonal imbalances.

Beyond weight management, GLP-1 agonists play a role in improving insulin sensitivity and addressing metabolic issues, both of which are common concerns for women with PCOS. Studies suggest that long-term use can help maintain weight loss and contribute to better overall health. However, it's worth noting that some weight regain might occur after discontinuing the medication. For women with PCOS, these treatments offer a science-supported approach to managing weight and enhancing overall quality of life.

What can I do to maintain weight loss after stopping GLP-1 medications?

To maintain your weight loss after stopping GLP-1 medications, sticking to healthy lifestyle habits is key. Prioritize a balanced diet, stay active with regular physical exercise, and aim for consistent, quality sleep. These routines not only support long-term weight management but also contribute to overall health.

In certain situations, your healthcare provider might suggest additional treatments, like metformin, to help maintain your results. While some weight regain can happen after discontinuing GLP-1 therapy, staying committed to these strategies can make a big difference in preserving your progress.

What serious side effects should I know about when using GLP-1 agonists?

While GLP-1 agonists are generally well-received by most users, there are some serious side effects you should be aware of. These can include severe gastrointestinal problems like nausea or vomiting, and in rare cases, pancreatitis. Another potential concern some individuals have noted is a change in facial appearance, often called 'Ozempic face.' This isn't caused by the medication itself but rather by the rapid weight loss that can occur.

If you have concerns, it’s crucial to talk with your healthcare provider. They can help you weigh the potential risks and benefits based on your specific health situation. Keep an eye on how your body reacts and report any unusual symptoms right away.